Gabather AB, receives Notice of Allowance from the U.S. Patent Office for its U.S. patent application publication No. US 2021/0087193 A1
Gabather AB (Nasdaq First North Growth Market: GABA), a clinical stage pharmaceutical company developing the next generation of therapeutics for neuropsychiatric disorders, is pleased to announce that it has received a Notice of Allowance from the U.S. Patent Office for its U.S. patent application publication No. US 2021/0087193 A1 entitled: Triazoloquinazolinone synthesis.The invention further increases and strengthens Gabather´s position in the field of GABA\A\ receptor modulators and methods of use. Gabather has a portfolio of patents and patent applications covering key products and